Literature DB >> 1827817

IL-4 increases IL-2 production by T cells in response to accessory cell-independent stimuli.

T Tanaka1, S Z Ben-Sasson, W E Paul.   

Abstract

Freshly prepared, highly purified T cells from naive mice failed to produce IL-2 in response to soluble anti-CD3 antibody or to Con A and produced only small amounts of IL-2 in response to anti-CD3 coated on the surface of microwells. IL-2 production in response to soluble anti-CD3 or to Con A required the addition of accessory cells. By contrast, the addition of IL-4 strikingly enhanced the production of IL-2 by plate-bound anti-CD3-stimulated T cells in the absence or the presence of added accessory cells. Furthermore, anti-IL-4 mAb inhibited IL-2 production by anti-CD3-stimulated T cells, which indicates that endogenously produced IL-4 was important in IL-2 production by T cells to plate-bound anti-CD3. The capacity of IL-4 to enhance and of anti-IL-4 to inhibit IL-2 production in response to plate-bound anti-CD3 was also observed with both unstimulated T cells and with T cells that had been previously stimulated with anti-CD3 antibody. When activated T cells were restimulated with anti-CD3, the effect of IL-4 in enhancing IL-2 production was detectable within 6 to 8 h after restimulation. The effect of IL-4 on IL-2 production was not due to prolongation of survival or to enhanced proliferation of T cells. Northern blot analysis showed that T cells treated with anti-CD3 plus IL-4 had more than 10-fold more IL-2 mRNA than did T cells treated with anti-CD3 plus anti-IL-4; this was observed within 6 h of stimulation under certain circumstances. The increased level of IL-2 mRNA by IL-4 was achieved without any change in message half-life, suggesting that IL-4 enhances transcriptional activation of the IL-2 gene in such cells. These results lead to the conclusion that IL-4 has a critical role in IL-2 production in response to accessory cell-independent stimuli (plate-bound anti-CD3 antibody), although it is not essential to IL-2 production in response to accessory cell-dependent stimuli (soluble anti-CD3 and Con A).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1827817

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Induction of the POU domain transcription factor Oct-2 during T-cell activation by cognate antigen.

Authors:  S M Kang; W Tsang; S Doll; P Scherle; H S Ko; A C Tran; M J Lenardo; L M Staudt
Journal:  Mol Cell Biol       Date:  1992-07       Impact factor: 4.272

2.  Plasma interleukin-3 and interleukin-4 concentrations in Turkish asthmatic children.

Authors:  N Kutukculer; E Ozdogru; E Demir; R Tanac
Journal:  Arch Dis Child       Date:  1995-10       Impact factor: 3.791

3.  Neonatal activation of CD28 signaling overcomes T cell anergy and prevents autoimmune diabetes by an IL-4-dependent mechanism.

Authors:  G A Arreaza; M J Cameron; A Jaramillo; B M Gill; D Hardy; K B Laupland; M J Rapoport; P Zucker; S Chakrabarti; S W Chensue; H Y Qin; B Singh; T L Delovitch
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

4.  Interleukin 4 suppresses interleukin 2 and interferon gamma production by naive T cells stimulated by accessory cell-dependent receptor engagement.

Authors:  T Tanaka; J Hu-Li; R A Seder; B Fazekas de St Groth; W E Paul
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

Review 5.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

6.  Role of IL-2 and IL-4 in exacerbations of murine antigen-induced arthritis.

Authors:  M J Jacobs; A E van den Hoek; P L van Lent; F A van de Loo; L B van de Putte; W B van den Berg
Journal:  Immunology       Date:  1994-11       Impact factor: 7.397

7.  Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice.

Authors:  M J Rapoport; A Jaramillo; D Zipris; A H Lazarus; D V Serreze; E H Leiter; P Cyopick; J S Danska; T L Delovitch
Journal:  J Exp Med       Date:  1993-07-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.